BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Something to consider, the new position for Director of Quality Assurance is to report directly to the President and CEO

July 18, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced the appointment of Sandra Croak-Brossman, MS, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance Dr. Croak-Brossman joins BioSante with over 24 years of experience in the pharmaceutical industry. She has held a variety of regulatory positions and has led operations at both a U.S. and global level. Dr. Croak-Brossman's work experience includes positions at Boehringer Ingelheim, Pfizer and Abbott Laboratories. Importantly, while at Pfizer, Dr. Croak-Brossman was the worldwide regulatory lead for Viagra®. Her experience as a regulatory lead in the sexual dysfunction therapeutic market makes her uniquely qualified to manage regulatory projects as BioSante progresses towards the NDA submission for LibiGel® (testosterone gel). Dr. Croak-Brossman earned her MS and Ph.D. in Quantitative Genetics and Animal Breeding from Purdue University and conducted her Post-Doctoral Fellowship at Cornell University.

On the fact sheet for the 14th Annual BIO CEO & Investor Conference, Dr. Croak-Brossma is listed as a vice president.

BIO Sheet

She may very well hold the VP of Quality Assurance until the Director is appointed.

Seeing Dr. Croak-Brossman's background and the elimination of her quality assurance duties,it leads me to believe that Biosante may very well be getting ready to have her concentrate fully on using her global regulatory expertise. If so this is going to be a fun stock to watch.